{
  "id": 16034304,
  "title": "Bristol Myers Squibb vs. Novo Nordisk: Stable Scale vs. GLP-1 Volatility",
  "url": "https://urgent.news/2026/10/22/bristol-myers-squibb-vs-novo-nordisk-stable-scale-vs-glp-1-volatility",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-22T11:10:01.000Z",
  "source": {
    "name": "Motley Fool",
    "slug": "motley-fool",
    "url": "https://www.fool.com/coverage/charts/2026/10/22/bristol-myers-squibb-vs-novo-nordisk-stable-scale-vs-glp-1-volatility/?source=iedfolrf0000001"
  },
  "original_language": "en",
  "account": "Bristol-Myers Squibb and Novo Nordisk, two leading pharmaceutical companies, showcase contrasting revenue models and growth strategies. Bristol-Myers Squibb primarily generates revenue from complex prescription drugs for cancer, cardiovascular issues, and immunological diseases. Recently, the company has invested billions of dollars to build a Texas manufacturing campus and secured accelerated FDA approval for a multiple myeloma treatment. In contrast, Novo Nordisk focuses on manufacturing and distributing medical treatments for diabetes and obesity, experiencing a recent FDA review period delay for a hemophilia treatment candidate. Both companies reported revenue over the past eight quarters, with Novo Nordisk experiencing a 32% jump in Q1 2026 due to the launch of its weight-loss pill Wegovy in the U.S. However, Novo Nordisk's revenue fell short in Q2 2026, dropping 6% following earnings, due to seasonality, pricing pressures, and slower new product sales. Despite the setback, Novo Nordisk's Ozempic and Wegovy account for 70% of its total sales, while Bristol-Myers Squibb's revenue growth comes from its growth portfolio, which now represents 58% of its revenue. Investors should consider the long-term potential of these companies, focusing on their diverse product lines and growth strategies rather than being swayed by quarterly results.",
  "summary": "Bristol Myers Squibb has led in seven of eight quarters, but Novo Nordisk's recent spike signals a shift worth watching for income-focused investors.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}